阿司匹林抵抗尚无特异性治疗方法。
针对阿司匹林抵抗的血小板功能检测合理吗？
Is platelet function testing for aspirin resistance reasonable to do?
结果302例患者中58例存在阿司匹林抵抗，占19.2%。
Results Of 302 cases, 58 cases developed aspirin resistance (19.2%).
多项临床试验证实，实验室阿司匹林抵抗和临床血管事件相关。
Clinical trials have shown that laboratory aspirin resistance is correlated with vascular events.
目的观察氯吡格雷对缺血性脑血管病患者阿司匹林抵抗（AR）的影响。
Objective To explore the effect of clopidogrel bisulfate on aspirin resistance (AR) in patients with ischemic cerebrovascular disease.
目的：探讨联合治疗对冠脉综合征(ACS)患者阿司匹林抵抗(AR)的疗效。
Objective: To study the effect of combine treatment on aspirin resistance (ar) in patients with acute coronary syndrome (ACS).
摘要：阿司匹林是抗血栓治疗的重要药物，阿司匹林抵抗是影响其疗效的常见原因。
ABSTRACT: aspirin is an important antithrombotic agent. However, its clinical benefit is impaired by aspirin resistance.
方法选取接受阿司匹林治疗的患者302例。根据血小板聚集率筛选阿司匹林抵抗患者。
Methods 302 cases treated with aspirin were selected according to platelet aggregation rate, who were divided by washing methods.
期望用同一机制解释所有的阿司匹林抵抗现象是不可行的，应当针对不同群体做更多的研究工作。
Expect to use the same mechanism to explain all the phenomena of aspirin resistance is not feasible, it should be for different groups to do more research.
结论通心络可以降低血小板聚集率，对于阿司匹林抵抗患者，选用通心络治疗可以取得一定的疗效。
Conclusion Tongxinluo may reduce platelet aggregation rate and produce certain therapeutic effect for the patients with aspirin resistance.
但到目前为止，仍无法用同一机制解释所有的阿司匹林抵抗，并且，很多研究所得出的结果是矛盾的。
So far, however, still can not explain all of the same mechanism of aspirin resistance, and many have to await its findings are contradictory.
但是，他们发现服用肠溶阿司匹林和阿司匹林抵抗之间没有关系，而以前有些研究却认为两者存在相关性。
However, they found no link between the use of enteric-coated aspirin and resistance to the drug; past studies, they note, have had "conflicting" findings on this point.
研究者指出，阿司匹林抵抗较常见于女性、老年人、肾功能不全、低血红蛋白和阿司匹林剂量偏小的患者。
Aspirin resistance was more common among women, older patients, patients with renal insufficiency, those with low hemoglobin levels and those on relatively low doses of aspirin, the researchers note.
平均随访379天后，阿司匹林抵抗患者的混合事件发生率为15.6%，而无阿司匹林抵抗患者的混合事件发生率为5.3%。
After an average of 379 days, the composite outcome was documented in 15.6% of the aspirin-resistant patients compared to 5.3% of patients who were not resistant to aspirin.
结论阿司匹林可改变老年胰岛素抵抗患者慢性炎症反应，从而降低CRP水平，改善胰岛素抵抗。
Conclusion Aspirin can change chronic inflammation in elderly patients with insulin resistance, and lower CRP, and improve insulin sensitivity.
结论阿司匹林可改变老年胰岛素抵抗患者慢性炎症反应，从而降低CRP水平，改善胰岛素抵抗。
Conclusion Aspirin can change chronic inflammation in elderly patients with insulin resistance, and lower CRP, and improve insulin sensitivity.
应用推荐